Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

SML2514

Sigma-Aldrich

Nedaplatin

Synonyme(s) :

Nedaplatin, Cis-Diammine (Glycolato)Platinum

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C2H8N2O3Pt
Numéro CAS:
Poids moléculaire :
303.17
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Forme

powder

Température de stockage

2-8°C

InChI

1S/C2H4O3.2H2N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H2;/q;2*-1;+2

Clé InChI

KLNFSAOEKUDMFA-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Nedaplatin is a second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. Nedplatin is less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin.

Pictogrammes

Skull and crossbonesHealth hazard

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1B - Skin Irrit. 2 - Skin Sens. 1B - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Takuma Kagami et al.
BMC cancer, 20(1), 1123-1123 (2020-11-22)
Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value of SLFN11 expression in esophageal squamous cell carcinoma
Hongmei Zhang et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 25(1), 80-86 (2020-04-12)
To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. A total of 100 ovarian cancer patients treated in our hospital from January 2015 to
Jun Fu et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 25(4), 1707-1713 (2020-10-26)
To investigate the efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer (SCLC). 64 patients diagnosed with SCLC in our hospital from April 2013 to June 2015 were retrospectively analyzed. Thirty-two patients in
Haruka Miyata et al.
Japanese journal of clinical oncology, 50(5), 609-616 (2020-01-20)
Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy
Osamu Maeda et al.
Anticancer research, 40(5), 2497-2507 (2020-05-06)
Spectrin αII contributes to cisplatin and carboplatin resistance in ovarian serous carcinoma cells, and its expression in surgical specimens is a valid predictor of prognosis. We sought to identify effective drugs for spectrin αII-mediated cisplatin-resistant cells. We employed SKOV3 cells

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique